TY - JOUR
T1 - K88 fimbrial adhesin targeting of microspheres containing gentamicin made with albumin glycated with lactose
AU - Sarabia-Sainz, Andre I.
AU - Sarabia-Sainz, Andre I.
AU - Sarabia-Sainz, Hector Manuel
AU - Montfort, Gabriela Ramos Clamont
AU - Mata-Haro, Veronica
AU - Guzman-Partida, Ana María
AU - Guzman, Roberto
AU - Garcia-Soto, Mariano
AU - Vazquez-Moreno, Luz
N1 - Publisher Copyright:
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2015/9/16
Y1 - 2015/9/16
N2 - The formulation and characterization of gentamicin-loaded microspheres as a delivery system targeting enterotoxigenic Escherichia coli K88 (E. coli K88) was investigated. Glycated albumin with lactose (BSA-glucose-β (4-1) galactose) was used as the microsphere matrix (MS-Lac) and gentamicin included as the transported antibiotic. The proposed target strategy was that exposed galactoses of MS-Lac could be specifically recognized by E. coli K88 adhesins, and the delivery of gentamicin would inhibit bacterial growth. Lactosylated microspheres (MS-Lac1, MS-Lac2 and MS-Lac3) were obtained using a water-in-oil emulsion, containing gentamicin, followed by crosslinking with different concentrations of glutaraldehyde. Electron microscopy displayed spherical particles with a mean size of 10–17 μm. In vitro release of gentamicin from MS-Lac was best fitted to a first order model, and the antibacterial activity of encapsulated and free gentamicin was comparable. MS-Lac treatments were recognized by plant galactose-specific lectins from Ricinus communis and Sophora japonica and by E. coli K88 adhesins. Results indicate MS-Lac1, produced with 4.2 mg/mL of crosslinker, as the best treatment and that lactosylated microsphere are promising platforms to obtain an active, targeted system against E. coli K88 infections.
AB - The formulation and characterization of gentamicin-loaded microspheres as a delivery system targeting enterotoxigenic Escherichia coli K88 (E. coli K88) was investigated. Glycated albumin with lactose (BSA-glucose-β (4-1) galactose) was used as the microsphere matrix (MS-Lac) and gentamicin included as the transported antibiotic. The proposed target strategy was that exposed galactoses of MS-Lac could be specifically recognized by E. coli K88 adhesins, and the delivery of gentamicin would inhibit bacterial growth. Lactosylated microspheres (MS-Lac1, MS-Lac2 and MS-Lac3) were obtained using a water-in-oil emulsion, containing gentamicin, followed by crosslinking with different concentrations of glutaraldehyde. Electron microscopy displayed spherical particles with a mean size of 10–17 μm. In vitro release of gentamicin from MS-Lac was best fitted to a first order model, and the antibacterial activity of encapsulated and free gentamicin was comparable. MS-Lac treatments were recognized by plant galactose-specific lectins from Ricinus communis and Sophora japonica and by E. coli K88 adhesins. Results indicate MS-Lac1, produced with 4.2 mg/mL of crosslinker, as the best treatment and that lactosylated microsphere are promising platforms to obtain an active, targeted system against E. coli K88 infections.
KW - Gentamicin
KW - Lactosylated microspheres
KW - Targeted active drug
UR - http://www.scopus.com/inward/record.url?scp=84942063780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942063780&partnerID=8YFLogxK
U2 - 10.3390/ijms160922425
DO - 10.3390/ijms160922425
M3 - Article
C2 - 26389896
AN - SCOPUS:84942063780
SN - 1661-6596
VL - 16
SP - 22425
EP - 22437
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 9
ER -